

ROLE OF MSCT FOR ACUTE CHEST PAIN: UPDATE 2023

BS CK II. Nguyễn Xuân Trình Department of Cardiology- MEDIC Medical Center



CÔNG TY TNHH Y TẾ HỎA HẢO - PHÒNG KHẢM ĐA KHOA (Tên cũ: TRUNG TÂM CHẨN ĐOÀN Y KHOA - MEDIC) 254 Hòa Hảo, P.4, Q.10, TP. Hồ Chí Minh DT: 028.39270284 - 028.39272136, Mail: hoahao254@medic.com.vn



QRCode kết quả _____

MEDIC

Họ tên:	Năm sinh: 1972 - Nam
Địa chỉ:	ĐT:
Nghể nghiệp: Công nhân	Số thẻ BHYT:

PHIẾU KHÁM BỆNH

KHOA TIM MẠCH - PHÒNG: 1

Huyết áp - Mạch: 110/67 - 79 (08:10) Cao: 152 cm; Nặng: 76 kg; Nhiệt độ: 37°C Tiền sử bệnh: THUỐC LÁ 1/2 GÓI/ NGÀY THA ĐANG DÙNG KHÔNG RÕ LOẠI Lý do đi khám: MỆT CẤP CỨU NHIỀU LẦN , TIM ĐẬP NHANH

CHİ ÐINH:

1. SIÊU ÂM (1): SA Tim Màu 2. ĐIỆN CHẨN ĐOÁN (2): Holter ECG ; Điện tâm đồ (ECG) 3. MRI-CT SCAN (1): MSCT Mach Vanh - Tim 4. KHÁM BÊNH (1): Khám CK Tim mạch

XÉT NGHIÊM-

EI NGHIĘM:				
Giờ	Người lấy mẫu			
ÔNG SỐ XÉT NGH	IỆM: 16			
NFS (C.B.C)	HbA1C	GGT	TSH (Thế hệ 3)	
AST (SGOT)	Triglycerides	eGFR (Độ Lọc (Cầu Thận) Free T4	Dình thường
ALT (SGPT)	LT (SGPT) LDL.C		Troponin - T hs	-Bình thường
rồng Phân Tích Nước Tiểu Glucose (Random)		Ion đổ chung	D - Dimer	
Hỉ ĐỊNH BỔ SUNC		Ν	igày 11 tháng 09 năm 2023 - 09:30 Bác sĩ	

2

ĐD. NGUYỄN THỊ HỔNG NHUNG

BS. CKII. NGUYẾN XUÂN TRÌNH

Case 1



CÔNG TY TNHH Y TẾ HỎA HẢO - PHÔNG KHẢM ĐA KHOA Coxo 11 FINI TE HOL HAO - FHORA MAN DA KHOA (Tén củ: TRUNG TÂN CHÂN ĐOÀN Y KHOA - MEDIC) 254 Hòa Hảo, P.4, Q.10, TP. Hồ Chi Minh DT: 028.39270284 - 028.39272136, Mail: hoahao254@medic.com.vn

Đãng ký khám trực tuyến : http://medichh.nthsoft.vn Hoặc app: Medic Hoa Hao

Qr code kết quả chứa bệnh án của quý khách. Medic không chịu trách nhiệm nếu quý khách cung cấp cho người khác.



KẾT QUẢ SIÊU ÂM TIM MÀU Máy: ALOKA -ProSound a6


MEDIC

ID Họ và tên 51 tuổi Nam Địa chỉ : 430 ma lo - f. binn fung fioa a - g. binn 1àn, Tp. Hcm – 0989774455 : Mệt Cấp Cứu Nhiều lần , tĩm Đập Nhanh Lâm sàng

VÙNG KHẢO SÁT : SIÊU ÂM TIM MÀU 1- Nhĩ trái dân nhẹ. Các buông tim khác trong giới hạn bình thưởng LVDd = 46 mm Loạn động vách liên thất và thành dưới. Chức năng thất trái bảo tôn EF= 60 % (Teichholz). Chức năng tâm thu thất phải TAPSE = 20 mm

2- Van 2 lá dầy ,hở 1/4-van ĐM chủ dầy ,hở 1/4 Không tăng áp động mạch phổi (PAPs= 28mmHg)


3- Không tràn dịch màng tim.



KÉT LUÂN : THEO DŌI BỆNH TIM THIẾU MÁU CỤC BỘ HỞ VAN 2 LÁ 1/4, HỎ VAN ĐM CHỦ 1/4


Đế nghị :

Tp. Hồ Chí Minh, ngày 11/09/2023 10:39 (Bác sĩ đã ký)






Case 1



Hẹp 90% RCA II




Case 2 : **Viêm cơ tim**, 34M, Mệt, Khó thở, EF giảm, tăng men tim - CT **Đánh giá động mạch vành**





Case 2: **Viêm cơ tim**, 34M, Mệt, Khó thở, EF giảm, tăng men tim - CT **Đánh giá cơ tim**






Case 2: Viêm cơ tim, 34M, Mệt, Khó thở, EF giảm, tăng men tim – MRI tim

*** KET LUAN:
HÌNH ẢNH TRÊN MRI: NGHĪ NHIỀU ĐẾN VIÊM CƠ TIM (THỎA TIÊU CHUẨN LAKE LOUISE 2018).
VÙNG CƠ TIM VIÊM: THÀNH TRƯỚC PHẨN GIỮA, VÁCH LIÊN THẤT GIỮA VÀ VÁCH MỎM, THÀNH BÊN PHẨN GIỮA VÀ PHẨN GẦN MỎM THẤT TRẢI + THÀNH TỰ DO THẤT PHẢI.
THẤT TRẢI DÂN NHỆ - GIẨM TRUNG BÌNH CHỨC NĂNG TẨM THU (LVEF=35%).
LGE (+): SEO XƠ HỎA XUYÊN THÀNH TOÀN BỘ THÀNH BÊN THẤT TRẢI, SEO XƠ HỎA Ở GIỮA THÀNH VÙNG VÁCH LIÊN THẮT GIỮA, VÁCH MÒM VÀ THÀNH TRƯỚC PHẨN GIỮA THẤT TRẢI, KHỔI LƯỢNG SEO 16 GRAM VÀ CHIẾM 18% KHỐI LƯỜNG CƠ TIM THẤT TRÁI.

> Tp. Hồ Chí Minh, ngày 07/03/2023 16:42 (Bác sĩ đã ký)





AHA/ACC CLINICAL PRACTICE GUIDELINE

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/ SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines




Figure 9. Evaluation Algorithm for Patients With Suspected ACS at Intermediate Risk With No Known CAD

Gulati et al. 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation.2021;144:e368–e454






Figure 10. Evaluation Algorithm for Patients With Suspected ACS at Intermediate Risk With Known CAD

Gulati et al. 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation.2021;144:e368-e454



European Heart Journal (2023) 00, 1–107 European Society of Cardiology

ESC GUIDELINES

S

2023 ESC Guidelines for the management of acute coronary syndromes

Recommendation Table 2 — Recommendations for non-invasive imaging in the initial assessment of patients with suspected acute coronary syndrome

Recommendations	Class ^a	Level ^b	
Emergency TTE is recommended in patients with suspected ACS presenting with cardiogenic shock or suspected mechanical complications.	I.	с	
In patients with suspected ACS, non-elevated (or uncertain) hs-cTn levels, no ECG changes and no recurrence of pain, incorporating CCTA or a non-invasive stress imaging test as part of the initial workup should be considered. ^{116,122–127}	lla	A	
Emergency TTE should be considered at triage in cases of diagnostic uncertainty but this should not result in delays in transfer to the cardiac catheterization laboratory if there is suspicion of an acute coronary artery occlusion.	lla	с	2023
Routine, early CCTA in patients with suspected ACS is not recommended. ¹¹⁷	ш	в	© ESC 2023



Table 2a Recommended chest pain pathways: Patients with No known CAD.

Chest Pain Level	Scenario	CAC (without cCTA)	cCTA*	cCTA + FFR-CT	cCTA + CTP	Notes
1	ECG diagnostic for STEMI					Door-to-balloon time <90 minutes
2	Leading Diagnosis NSTE-ACS • ST-changes suggestive of ischemia (no ST-elevation), leading diagnosis NSTE-ACS • Elevated cTn or hs-cTn (>99 th percentile)					Invasive coronary angiography; Coronary CTA is rarely indicated to determine if invasive evaluation is appropriate
3	High Risk for ACS • Normal or nonischemic ECG, <u>high</u> pretest risk for ACS**, and: • Normal or equivocal baseline cTn, or • hs-cTn <99 th percentile					Coronary CTA is an alternative to functional testing or invasive angiography
4	Low-to-Intermediate Risk for ACS Normal or nonischemic ECG, low-to-intermediate risk for ACS**, and: Normal or equivocal baseline CTn, or hs-CTn -99th percentile Inadequate or mildly abnormal functional testing during the index ED visit or within the previous 1 year 					Coronary CTA is most effective to rule-out ACS
5	Very Low Risk for ACS Normal or nonischemic ECG, <u>low</u> risk for ACS**, and: Normal hs-cTn, or Normal CTn, and leading diagnosis is non-cardiac chest pain 					Very low risk patients may not benefit from additional testing: Coronary CTA may be appropriate in some patients to confidently exclude CAD and provide risk stratification

Table 2b

Patients with documented CAD, post-revascularization.


Scenario		CAC (without cCTA)	cCTA*	cCTA + FFR- CT	cCTA + CTP
Prior PCI					
3-mnNorm	t within a proximal coronary segment and stent diameter ≥ n nal or nonischemic ECG nal or equivocal cTn or hs-cTn				
Prior CABG					
 Norm 	nal or nonischemic ECG				
 Norm 	nal or equivocal cTn or hs-cTn				

C.D. Maroules et al. Journal of Cardiovascular Computed Tomography 17 (2023) 146–163



CTA Imaging of Atherosclerotic Plaque (ACC 2021 Redefines Known CAD)

MEDIC



Michael J Gallagher (2023) . https://www.vumedi.com/term/ct/



CORONARY ARTERY CALCIUM (CAC) TESTING

- Coronary artery calcium (CAC) testing with non-contrast CT is rarely appropriate as a stand-alone test for the evaluation of ACP in the ED.
- When CAC= 0, the rate of obstructive CAD is low (less than 1%) and long-term prognosis is favorable.
- However, CAC = 0 cannot exclude ACS, which can occur in 1–3% of patients who have noncalcified plaque.

C.D. Maroules et al. Journal of Cardiovascular Computed Tomography 17 (2023) 146–163



> Heart. 2023 Apr 12;109(9):695-701. doi: 10.1136/heartjnl-2022-321682.

Coronary calcium score in the initial evaluation of suspected coronary artery disease

Eva Ringdal Pedersen ¹², Siren Hovland ², Iman Karaji ³², Christ Berge ², Abukar Mohamed Ali ², Ole Christian Lekven ², Kier Jan Kuiper ², Svein Rotevatn ², Terje Hjalmar Larsen ²⁴


- **Objective:** We evaluated coronary artery calcium (CAC) scoring as an initial diagnostic tool in outpatients and in patients presenting at the emergency department due to suspected coronary artery disease (CAD).
- Methods: 10 857 patients underwent CAC scoring and coronary CT angiography (CCTA)
- **Results:** the sensitivity, specificity, positive predictive value and negative predictive value (NPV) of CAC=0 for obstructive CAD were 95.3%, 53.4%, 30.0% and 98.2%, respectively. However, among patients <45 years of age, although the NPV was high at 98.9%, the sensitivity of CAC=0 for obstructive CAD was only 82.3%.
- Conclusions: In symptomatic patients, CAC=0 correctly ruled out obstructive CAD and high-risk CAD in 98.2% and 99.4% of cases. This large registry-based cross-sectional study supports the incorporation of CAC testing in the early triage of patients with chest pain and as a gatekeeper to further cardiac testing. However, a full CCTA may be needed for safely ruling out obstructive CAD in the youngest patients (<45 years of age).





Case 3:

53M, chest pain 1 week , hsTroponin T 0.25ng/L, PAPs=74mmHg PE /MSCT





Suspected PE

Table 3. Suspected PE					
Indication	CTPA	CompUS	VQ	PMRA	PCath
Likelihood by clinical scoring algorithm alone, patient not pregnant 11 o-dimer negative Not high likelihood by a clinical scoring algorithm	R	R	R	R	R
 D-dimer positive Not high likelihood by a clinical scoring algorithm High likelihood by a clinical scoring algorithm 	A A	M	A A	R R	R R
Pregnancy 14. Patient with leg symptoms 15. Patient with no leg symptoms	M* A	A M*	A A	R R	R R


Appropriate use key: A = appropriate; M = may be appropriate with rating panel consensus; M* = may be appropriate as determined by lack of consensus by rating panel; R = rarely appropriate.

 $\label{eq:CTPA} CTPA = CT pulmonary angiography; CompUS = compression ultrasonography of the deep veins; PCath = catheter-based pulmonary angiography; \\ PMRA = pulmonary MR angiography; VQ = ventilation-perfusion scan.$

Rybicki et al . Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain. J Am Coll Radiol 2016;13:e1-e29



CASE 4





Suspected AAS


Table 4. Suspected AAS					
Indication	CTAo	MRAo	TTE	TEE	AoCath
Hemodynamically unstable patient 16. Prior or no prior aorta intervention	A	M*	M*	M*	M*
Hemodynamically stable patient 17. No prior aorta intervention 18. Prior aorta intervention	AA	A A	M M	A M*	R M*

Appropriate use key: A = appropriate; M = may be appropriate with rating panel consensus; M* = may be appropriate as determined by lack of consensus by rating panel; R = rarely appropriate.

AoCath = catheter-based aortography; CTAo = CT aortography; MRAo = MR aortography; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography.


Rybicki et al . Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain. J Am Coll Radiol 2016;13:e1-e29







Triple Rule-Out (TRO) CTA





US Cardiology Review

REVIEW Acute Coronary Syndromes

© RADCLIFFE CARDIOLOGY 2022 www.USCjournal.com

Role of Coronary CT Angiography in the Evaluation of Acute Chest Pain and Suspected or Confirmed Acute Coronary Syndrome

Tasveer Khawaja, MD, 🖲, Scott Janus, MD, 🖲, and Sadeer G Al-Kindi, MD 🕲

Department of Medicine, Harrington Heart & Vascular Institute, University Hospitals, Cleveland, OH

Figure 1: Forest Plot from a Meta-analysis of MI Following Coronary CT Angiography Versus Standard Care in Stable and Acute Chest Pain

	CCTA Usual care OR					OR				
Study or subgroup	Events	Total	Events	Total	Weight	M-H Fixed 95% Cl	Year	M-H Fixed 95% CI		
2.5.1 Acute chest pain										
CT-STAT (2011)10	1	330	5	297	5.0%	0.18 [0.02, 1.53]	2014			
PROSPECT (2015)15	9	209	9	200	8.1%	1.00 [0.39, 2.57]	2015			
CATCH (2015) ¹⁴	2	285	7	291	6.5%	0.29 [0.06, 1.39]	2015			
ACRIN-PA (2016)49	11	870	5	444	6.2%	1.12 [0.39, 3.26]	2016			
PERFECT (2016)50	2	206	1	205	0.9%	2.00 [0.18, 22.23]	2016			
Subtotal (95% CI)		1891		1437	26.7%	0.74 [0.42, 1.29]		-		
Total events	25		27							
Heterogeneity: x ² =4.72, d.f.=4	(p=0.32);	l ² =15%								
Test for overall effect: Z=1.06	(p=0.29)									
2.5.2 Stable chest pain										
PROMISE (2015)51	30	4996	40	5007	37.5%	0.75 [0.47, 1.21]	2015			
CAPP (2015)52	1	243	2	245	1.9%	0.5 [0.05, 5.57]	2015			
SCOT-HEART (2015)53	22	2073	35	207	32.7%	0.62 [0.37, 1.07]	2015			
CRESCENT (2016)54	1	239	1	108	1.3%	0.45 [0.03, 7.26]	2016			
Subtotal (95% CI)		27551		7433	73.3%	0.68 [0.48, 0.97]		•		
Total events	54		78							
Heterogeneity: x ² =0.41, d.f.=3	(p=0.94);	² =0%								
Test for overall effect: Z=2.15	(p=0.03)									
Total (95% CI)		9442		8870	100.0%	0.70 [0.52, 0.94]		◆		
Total events	79		105							
Heterogeneity: x ² =5.26, d.f.=8	3 (p=0.73);	12=0%								
Test for overall effect: Z=2.39	(p=0.02)						0.01	0.1 1 10 100		
Test for subgroup differences	s: x ² =0.05,	d.f.=1 (p=		Favors CCTA Favors usual care						



MEDIC

Radiology: Cardiothoracic Imaging



Comparative Effectiveness of Coronary CT Angiography and Standard of Care for Evaluating Acute Chest Pain: ${\rm A}$

Living Systematic Review and Meta-Analysis

Mauricio F. Barbosa, MD, PhD • Arzu Canan, MD • Yin Xi, PhD • Harold Litt, MD, PhD • Deborah B. Diercks, MD, MSc • Sulmy Abbara, MD • Fernando U. Kay, MD, PhD

		CCTA			SOC							
Study	Total	Mean	SD	Total	Mean	SD		Ratio of	Means	ROM	95%-Cl	Weight
Risk for ACS = Group 1								: 1				
Goldstein et al. (2007)												0.0%
Miller et al. (2011)	30	72.00	74.40	30	99.90	93.60		- 60		0.72	[0.44; 1.19]	2.9%
Goldstein et al. (2011)												0.0%
Hoffmann et al. (2012)	501	23.20	37.00	499	30.80	28.00				0.75	[0.64; 0.88]	8.7%
Litt et al. (2012)	908	18.00	14.50	462	24.80	8.40		H		0.73	[0.68; 0.77]	11.0%
Hamilton-Craig et al. (2014)	322	13.50	3.30	240	19.70	3.50				0.69	[0.66; 0.71]	11.3%
Levsky et al. (2015)	200	28.90	27.70	200	30.40	20.20		- 100	_	0.95	[0.81; 1.12]	8.7%
Dedic et al. (2016)	250	6.30	4.60	250	6.30	15.50			3	1.00	[0.73; 1.37]	5.2%
Nabi et al. (2016)	288	19.70	27.80	310	23.50	34.40		-18	-	0.84	[0.67; 1.06]	7.0%
Hollander et al. (2016)								1				0.0%
Uretsky et al. (2017)	206	48.00	40.00	205	49.00	48.00				0.98	[0.82; 1.17]	8.4%
Chang et al. (2017)												0.0%
Levsky et al. (2018)	201	5.80		199	4.90					1.18		0.0%
Goldman et al. (2020)												0.0%
Pineiro-Portela et al. (2021)												0.0%
Aziz et al. (2022)	125	7.53	2.70	125	8.14	2.60		1000		0.93	[0.85; 1.01]	10.6%
Random effects model	3031			2520				0		0.83	[0.74; 0.92]	73.7%
Heterogeneity: $I^2 = 88\%$, $\tau^2 = 0$	0.0176,	p < 0.0	1									
Risk for ACS = Group 2												
Chang et al. (2008)	133	4.60	2.90	133	4.80	3.30				0.96	[0.82; 1.12]	8.8%
Linde et al. (2013)												0.0%
Linde et al. (2015)												0.0%
Smulders et al. (2019)	70	96.00	72.00	69	120.00	72.00		- 12		0.80	[0.64; 1.00]	7.1%
Gray et al. (2021)	877	52.80	52.80	871	48.00	48.00			and the second s	1.10	[1.00; 1.21]	10.4%
Gray et al. (2022)											•	0.0%
Random effects model	1080			1073				~	>	0.97	[0.81; 1.15]	26.3%
Heterogeneity: $I^2 = 73\%$, $\tau^2 = 0$	0.0171,	p = 0.0	2									
Random effects model	4111			3593				\$		0.86	[0.78; 0.95]	100.0%
Heterogeneity: $I^2 = 92\%$, $\tau^2 = 0$		p < 0.0	1				L			۰··· ۲		
Test for subgroup differences:				.13)			0.5	1		2		

Figure 2: Comparison of the length of stay between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the ratio of means (ROM) for length of stay (in hours) for CCTA compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall ratio of means was 0.86 (95% CI: 0.78, 0.95). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.

		CCTA			SOC					
Study	Total	Mean	SD	Total	Mean	SD	Ratio of Means	ROM	95%-Cl	Weight
Risk for ACS = Group 1							11			
Goldstein et al. (2007) Miller et al. (2011) Goldstein et al. (2011)	361	1586.00 10134.00 2137.00	1050.00	338	3458.00	253.00 19148.00 1035.00		0.61 0.62	[0.80; 0.90] [0.32; 1.17] [0.58; 0.66]	13.1% 3.3% 13.2%
Hoffmann et al. (2012) Litt et al. (2012)	501	4289.00	7110.00	499	4060.00	5452.00		1.06	[0.88; 1.27]	10.8% 0.0%
Hamilton-Craig et al. (2014) Levsky et al. (2015)		1406.00	186.00	240	1734.00	141.00	<u>.</u>		[0.80; 0.83]	13.5% 0.0%
Dedic et al. (2016) Nabi et al. (2016)	250 288	337.00 4242.00	440.00 3871.00	250 310	511.00 5104.00	450.00 3703.00			[0.54; 0.80] [0.73; 0.95]	10.6% 12.0%
Hollander et al. (2016) Uretsky et al. (2017)				1	:	•	Ī			0.0% 0.0%
Chang et al. (2017) Levsky et al. (2018)				1		-				0.0% 0.0%
Goldman et al. (2020) Pineiro-Portela et al. (2021)	100	3003.00	4080.00	103	3834.00	5310.00		0.78	[0.54; 1.14]	0.0% 6.7%
Aziz et al. (2022) Random effects model	125 2076	1475.00	2544.00	125 1993	1272.00	4103.00	¢		[0.61; 2.20] [0.70; 0.90]	3.4% 86.5%
Heterogeneity: $I^2 = 91\%$, $\tau^2 = 0$	0257.	0 < 0.01								
Risk for ACS = Group 2										
Chang et al. (2008) Linde et al. (2013)	÷									0.0% 0.0%
Linde et al. (2015)				1	1					0.0%
Smulders et al. (2019) Gray et al. (2021)										0.0%
Gray et al. (2022)	877	7330.00	840.00	871	6767.00	743.00		1.08	[1.07; 1.09]	13.5%
Random effects model Heterogeneity: $I^2 = 99\%$, $\tau^2 = 0$	2953	0 < 0.01		2864			÷	0.83	[0.72; 0.95]	100.0%
Test for subgroup differences: ;			< 0.01)				0.5 1 2			

Figure 9: Comparison of costs between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the ratio of means (ROM) for costs (U.S. dollars) for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall ROM was 0.83 (95% CI: 0.72, 0.95). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.



Advantages of CT First in the ED



ED decompression, faster time-to-discharge



Improved outcomes

Lower costs

Exclude other lifethreatening disease



CONCLUSION: CCTA in the ACP

- CCTA has a high sensitivity (98-100%), Specificity 85%, NPV 100%.
- Combined High-risk plaque features and PCAT CT attenuation may allow for Risk Stratification of Patients With Acute Chest Pain
- CCTA as first test for low-intermediate risk pts with potential ACS
- Combination of hs Troponins and CCTA may play a valuable role in future strategies for the management of patients with ACP.
- CCTA demonstrated effectiveness as a safety strategy for evaluation of participants presenting with ACP
- The use of CCTA in low- to intermediate-risk participants was associated with a 17% reduction in length of stay and a 21% decrease in immediate costs





Thank You